Abacus Wealth Partners LLC Sells 680 Shares of Becton, Dickinson and Company (NYSE:BDX)

Abacus Wealth Partners LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 33.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,343 shares of the medical instruments supplier’s stock after selling 680 shares during the period. Abacus Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $324,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BDX. Park Avenue Securities LLC boosted its holdings in Becton, Dickinson and Company by 27.2% during the third quarter. Park Avenue Securities LLC now owns 2,735 shares of the medical instruments supplier’s stock valued at $659,000 after acquiring an additional 584 shares during the period. Canandaigua National Bank & Trust Co. raised its position in shares of Becton, Dickinson and Company by 3.4% during the third quarter. Canandaigua National Bank & Trust Co. now owns 4,085 shares of the medical instruments supplier’s stock valued at $985,000 after buying an additional 134 shares during the last quarter. Czech National Bank raised its position in shares of Becton, Dickinson and Company by 6.9% during the third quarter. Czech National Bank now owns 58,880 shares of the medical instruments supplier’s stock valued at $14,196,000 after buying an additional 3,808 shares during the last quarter. Central Pacific Bank Trust Division raised its position in shares of Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 45 shares during the last quarter. Finally, Park National Corp OH raised its position in shares of Becton, Dickinson and Company by 4.8% during the third quarter. Park National Corp OH now owns 39,259 shares of the medical instruments supplier’s stock valued at $9,465,000 after buying an additional 1,814 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James dropped their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Evercore ISI raised their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the company from $255.00 to $275.00 in a report on Tuesday. Finally, Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Stock Performance

BDX opened at $237.35 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The business’s 50-day moving average price is $236.64 and its two-hundred day moving average price is $235.58. The company has a market capitalization of $68.59 billion, a price-to-earnings ratio of 52.28, a P/E/G ratio of 1.92 and a beta of 0.42. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.96 earnings per share. Equities analysts expect that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date of this dividend was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.